Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Chubb Ltd (CB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Chubb Ltd — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Chubb Ltd trades at $358.25 (market cap $139.36B). The key difference: Chubb Ltd is far larger — about 31× ACADIA Pharmaceuticals Inc.'s market cap, and Chubb Ltd pays a 1.14% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | CB | |
|---|---|---|
Market Cap | $4.49B | $139.36B |
Sector | Health | Financials |
52-Week High | $28.06 | $361.17 |
52-Week Low | $20.06 | $265.99 |
Enterprise Value | $3.69B | $160.41B |
Dividend Yield | — | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Chubb (CB) trades at $359.30, down 0.52% on the day but near its 52-week high, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with consistent earnings beats, revenue growth from $59.78B in 2025 to projected $61.2B in 2026, and a net income margin of 18.46%. Recent news highlights premium growth and disciplined underwriting as key strengths.
Outlook remains positive with analyst consensus favoring Buy ratings (52.38%) and a price target of $341.90, though risks include catastrophe losses and softer commercial pricing. The stock's valuation at P/E 12.61 offers value, but investors should monitor Q2 2026 earnings due July 22, 2026, for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Chubb Ltd
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination makes the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
Read more on CB →
